Biogen Idec Taps Exelixis' Scangos To Be New CEO
Executive Summary
Exelixis’s long-time CEO George Scangos, PhD, is taking the the helm of Biogen Idec. The move is counterintuitive, both for the commercial stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.
You may also be interested in...
Biogen Idec Charts A New Course
Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri
Biogen Idec Charts A New Course
Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri
Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.